A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human follicle-stimulating hormone and human chorionic gonadotropin.

Warne DW, Decosterd G, Okada H, Yano Y, Koide N, Howles CM

Fertility and sterility18 Oct 2008Cited by 82 (Europe PMC)

PMID18930225DOI10.1016/j.fertnstert.2008.07.1720PepBankPUB-18930225

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

1 result from studies that gave the peptide. 1 result from people.

01HumanNon-randomized trialEfficacy outcome
In men with hypogonadotropic hypogonadism, 81 men remained azoospermic but achieved normal serum testosterone after hCG pretreatment.
In plain wordsIn men with hypogonadotropic hypogonadism, 81 men still had no sperm but reached normal blood testosterone after hCG pretreatment.
Peptide
hCG (human chorionic gonadotropin)
Outcome
IncreaseAzoospermic men with normal serum testosterone after hCG pretreatment
Study
n = 100
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · 3-6 monthsAs given in this study (human).
Measurements
Men remaining azoospermic with normal serum testosterone
81 men
After hCG pretreatment
Source sentences
Summary
A total of 81 men remained azoospermic but achieved normal serum T concentrations after hCG pretreatment.
3 context sentences(design, population, supporting numbers)
Summary · context
A combined analysis of data from four clinical trials.
Summary · context
Phase III, open-label, noncomparative studies with similar designs conducted in Australia, Europe, Japan, and the United States.
Summary · context
Pretreatment with hCG for 3-6 months, followed by combination therapy with hCG and r-hFSH (150 IU three times weekly) for up to 18 months.
Report a problemFND-1893022501

Studies that did not test the peptide alone4

In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking hCG (human chorionic gonadotropin).

02HumanNot a test of hCG (human chorionic gonadotropin) aloneNon-randomized trialEfficacy outcome
In men with hypogonadotropic hypogonadism, combined hCG and r-hFSH achieved sperm concentrations >or=1.5 x 10(6)/mL in 56 men (69.1%).
In plain wordsIn men with hypogonadotropic hypogonadism, 69.1% reached the specified sperm concentration threshold with combined hCG and FSH.
Peptide
hCG (human chorionic gonadotropin)
Outcome
IncreaseSperm concentration threshold
Study
n = 81
Analysis
Primary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Men achieving spermatozoa concentration threshold
56 men
Combined hCG and r-hFSH after hCG pretreatment
Proportion achieving spermatozoa concentration threshold
69.1%
Combined hCG and r-hFSH after hCG pretreatment
Source sentences
Summary
Of these, 68 (84.0%) achieved spermatogenesis and 56 (69.1%) achieved spermatozoa concentrations >or=1.5 x 10(6)/mL.
3 context sentences(design, population, supporting numbers)
Summary · context
A combined analysis of data from four clinical trials.
Summary · context
Phase III, open-label, noncomparative studies with similar designs conducted in Australia, Europe, Japan, and the United States.
Summary · context
Pretreatment with hCG for 3-6 months, followed by combination therapy with hCG and r-hFSH (150 IU three times weekly) for up to 18 months.
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-1893022504
03HumanNot a test of hCG (human chorionic gonadotropin) aloneNon-randomized trialEfficacy outcome
In men with hypogonadotropic hypogonadism after hCG pretreatment, combined hCG and r-hFSH therapy achieved spermatogenesis in 68 men (84.0%).
In plain wordsIn men with hypogonadotropic hypogonadism, combined hCG and FSH restored sperm production in 84.0% after hCG pretreatment.
Peptide
hCG (human chorionic gonadotropin)
Outcome
IncreaseSpermatogenesis
Study
n = 81
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Men achieving spermatogenesis
68 men
Combined hCG and r-hFSH after hCG pretreatment
Proportion achieving spermatogenesis
84%
Combined hCG and r-hFSH after hCG pretreatment
Source sentences
Summary
Of these, 68 (84.0%) achieved spermatogenesis and 56 (69.1%) achieved spermatozoa concentrations >or=1.5 x 10(6)/mL.
3 context sentences(design, population, supporting numbers)
Summary · context
A combined analysis of data from four clinical trials.
Summary · context
Phase III, open-label, noncomparative studies with similar designs conducted in Australia, Europe, Japan, and the United States.
Summary · context
Pretreatment with hCG for 3-6 months, followed by combination therapy with hCG and r-hFSH (150 IU three times weekly) for up to 18 months.
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-1893022503
04HumanNot a test of hCG (human chorionic gonadotropin) aloneNon-randomized trialOther
In men receiving combined hCG and r-hFSH, larger baseline testes, lower body mass index, and advanced sexual maturity predicted good response.
In plain wordsIn men receiving combined hCG and FSH, larger testes, lower body mass index, and greater sexual maturity predicted better response.
Peptide
hCG (human chorionic gonadotropin)
Outcome
Direction not reportedPredictors of therapy response
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
Large baseline mean testicular volume, low body mass index, and advanced sexual maturity were predictors of good response to therapy.
3 context sentences(design, population, supporting numbers)
Summary · context
A combined analysis of data from four clinical trials.
Summary · context
Phase III, open-label, noncomparative studies with similar designs conducted in Australia, Europe, Japan, and the United States.
Summary · context
Pretreatment with hCG for 3-6 months, followed by combination therapy with hCG and r-hFSH (150 IU three times weekly) for up to 18 months.
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-1893022505
05HumanNot a test of hCG (human chorionic gonadotropin) aloneNon-randomized trialEfficacy outcome
In men with hypogonadotropic hypogonadism, responses to hCG and r-hFSH therapy were similar across study populations.
In plain wordsIn men with hypogonadotropic hypogonadism, combined hCG and FSH treatment responses were similar across study populations.
Peptide
hCG (human chorionic gonadotropin)
Outcome
No significant changeResponse across populations
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
Similar treatment responses were observed across different study populations.
3 context sentences(design, population, supporting numbers)
Summary · context
A combined analysis of data from four clinical trials.
Summary · context
Phase III, open-label, noncomparative studies with similar designs conducted in Australia, Europe, Japan, and the United States.
Summary · context
Pretreatment with hCG for 3-6 months, followed by combination therapy with hCG and r-hFSH (150 IU three times weekly) for up to 18 months.
In this study, hCG (human chorionic gonadotropin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking hCG (human chorionic gonadotropin).
Report a problemFND-1893022506

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.